UCHL1 Is a Parkinson's Disease Susceptibility Gene

Annals of Neurology

Volumn 55, Issue 4, 2004, Pages 512-521

  Maraganore, Demetrius M ^a,m   Lesnick, Timothy G ^a   Elbaz, Alexis ^b   Chartier Harlin, Marie Christine ^b   Gasser, Thomas ^c   Krüger, Rejko ^c   Hattori, Nobutaka ^d   Mellick, George D ^e   Quattrone, Aldo ^f,g   Satoh, Jun Ichi ^h   Toda, Taksushi ⁱ   Wang, Jian ^j   Ioannidis, John P A ^k,l   De Andrade, Mariza ^a   Rocca, Walter A ^a  

^a MAYO CLINIC   (United States)

^b INSERM   (France)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^g INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^h NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

ⁱ OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j STONY BROOK UNIVERSITY   (United States)

^k UNIVERSITY OF IOANNINA   (Greece)

^l TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Mayo Clinic   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ARTICLE; CONFIDENCE INTERVAL; DISEASE PREDISPOSITION; DRUG TARGETING; GENE; GENE DOSAGE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPOTHESIS; MOLECULAR GENETICS; PARKINSON DISEASE; PRIORITY JOURNAL; PUBLICATION; STATISTICAL SIGNIFICANCE; UCHL1 GENE;

EID: 12144289221     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20017     Document Type: Article

References (38)

1. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-452.
2. Lincoln S, Vaughan J, Wood N, et al. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 1999;10: 427-429.
3. Maraganore DM, Farrer MJ, Hardy JA, et al. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999;53:1858-1860.
4. Solano SM, Miller DW, Augood SJ, et al. Expression of α-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann Neurol 2000;47:201-210.
5. Jackson P, Thompson RJ. The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis. J Neurol Sci 1981;49: 429-438.
6. McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 2003;53(suppl 3):S73-S86.
7. McNaught KSP, Mytilineou C, JnoBaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002;81:301-306.
8. Mellick GD, Silburn PA. The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease. Neurosci Lett 2000; 293:127-130.
9. Levecque C, Destée A, Mouroux V, et al. No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J Neural Transm 2001;108:979-984.
10. Savettieri G, De Marco EV, Civitelli D, et al. Lack of association between ubiquitin carboxy-terminal hydrolase L1 gene polymorphism and PD. Neurology 2001;57:560-561.
11. Gasser T, Pilz P, Omasmeier D, et al. Ubiquitin C-terminal hydrolase L1 in sporadic Parkinson's disease. Mov Disord 2000; 15:A201.
12. Zhang J, Hattori N, Leroy E, et al. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Rel Disord 2000;6:195-197.
13. Wang J, Zhao C-Y, Si Y-M, et al. ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov Disord 2000;17:767-771.
14. Elbaz A, Levecque C, Clavel J, et al. S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. Mov Disord 2003;18:130-137.
15. Wintermeyer P, Kruger R, Kuhn W, et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport 2000;11:2079-2082.
16. Satoh J-I, Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J Neurol Sci 2001;189:113-117.
17. Momose Y, Murata M, Kobayashi K, et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 2002;51: 133-136.
18. Wolfinger R, O'Connell M. Generalized linear mixed models: a pseudo-likelihood approach. J Stat Comput Simulation 1993; 48:233-243.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
20. DerSimonian R, Laird N. Meta-analysis on clinical trials. Control Clin Trials 1986;7:177-188.
21. Ioannidis JPA, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29:306-309.
22. Ioannidis JPA, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci USA 2001;98:831-836.
23. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology. A proposal for reporting. JAMA 2000;283:2008-2012.
24. Little J, Khoury MJ, Bradley L, et al. The Human Genome Project is complete. How do we develop a handle for the pump? Am J Epidemiol 2003;157:667-673.
25. Lohmueller KE, Pearce CL, Pike M, et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33:177-182.
26. Attia J, Thakkinstian A, D'Este C. Meta-analysis of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 2003;56:297-303.
27. Rocca WA. Analysis, reanalysis, and meta-analysis in neurology. In: Hofman A, Mayeux R, eds. Investigating neurological diseases: epidemiology for clinical neurology. Cambridge, UK: Cambridge University Press, 2001:26-42.
28. Little J, Bradley L, Bray MS, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002;156:300-310.
29. Ioannidis JPA, Rosenberg PS, Goedert JJ, O'Brien TR. Commentary: meta-analysis of individual participants' data in genetic epidemiology. Am J Epidemiol 2002;156:204-210.
30. Freely associating. Nat Genet 1999;22:1-2.
31. Thornton A, Lee P. Publication bias in meta-analysis: its cause and consequences. J Clin Epidemiol 2000;53:207-216.
32. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361:567-571.
33. Knowler WC, Williams RC, Pettitt DJ, Steinberg AG. Gm3; 5,13,14 and type 2 diabetes mellitus: an association in American Indians with genetic admixture. Am J Hum Genet 1988; 43:520-526.
34. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Genet 2001;2:91-98.
35. Farrer M, Destee A, Becquet E, et al. Linkage exclusion in French families with probable Parkinson's disease. Mov Disord 2000;15:1075-1083.
36. Liu Y, Fallon L, Lashuel HA, et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 2002;111: 209-218.
37. Maraganore DM, de Andrade M, Lesnick TG, et al. Complex interactions in Parkinson's disease: a two-phased approach. Mov Disord 2003;18:631-636.
38. Farrer M, Maraganore DM, Lockhart P, et al. α-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001;10:1847-1851.